AzTrials
AzTrials

CoccydyniaESWTNCT02313324

The Effects of Extracorporeal Shock Wave Therapy in Patients With Coccydynia: A Randomized Controlled Trial

A study testing Extracorporeal shock wave therapy (ESWT) and SWD combined IFC in people with Coccydynia, run by Kaohsiung Medical University Chung-Ho Memorial Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the effects of extracorporeal shock wave therapy (ESWT) on the outcomes of coccydynia. Read more about this study

Who is it for?
Ages 20 to 83 years
Conditions the study is for
Coccydynia
What is being tested?
Extracorporeal shock wave therapy (ESWT) and SWD combined IFC
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
42 participants
Where
No sites listed yet
Study dates
Nov 2012to Nov 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 83 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • First-time diagnosed with coccydynia
  • History of direct traumatic events to the buttocks, such as falls or slipping

Who cannot join

  • Tumors of the cauda equina
  • Pelvic surgery
  • Herniation of the lumbosacral disc
  • Internal procidentia
  • Genitourinary or gastrointestinal complaints
  • Psychogenic factors

About this study

The purpose of this study is to evaluate the effects of extracorporeal shock wave therapy (ESWT) on the outcomes of coccydynia.

Read the detailed description

Coccydynia is pain in the coccygeal region, and usually treated conservatively. Extracorporeal shock wave therapy (ESWT) was incorporated as non-invasive treatment of many musculoskeletal conditions. However, the effects of ESWT on coccydynia are less discussed. The purpose of this study is to evaluate the effects of ESWT on the outcomes of coccydynia. Patients were allocated to ESWT (n=20) or physical modality (SIT) group (n=21) randomly, and received total treatment duration of 4 weeks. The visual analog scale (VAS), Oswestry disability index (ODI), and self-reported satisfaction score were used to assess treatment effects. The VAS and ODI scores were significantly decreased after treatment in both groups, and the decrease in the VAS score was significantly greater in the ESWT group. The mean proportional changes in the ODI scores were greater in the ESWT group than in the SIT group, but the between-group difference was not statistically significant. The patients in the ESWT group had significantly higher subjective satisfaction scores than SIT group. The investigators concluded that ESWT is more effective and satisfactory in improving discomfort and disability caused by coccydynia than the use of physical modalities. Thus, ESWT is recommended as an optimal treatment option for patients with coccydynia.

Conditions
Coccydynia
Being tested
Extracorporeal shock wave therapy (ESWT), SWD combined IFC
Keywords
Coccydynia, Extracorporeal shock wave therapy, Disability

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Extracorporeal shock wave therapy (ESWT)Device

    The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.

  • SWD combined IFCDevice

    The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.

Study groups in NCT02313324
Study groupRoleWhat they receive
ESWT groupExperimentalThe patients were randomly assigned to the extracorporeal shock wave therapy (ESWT) group.
Receives: Device: Extracorporeal shock wave therapy (ESWT)
SWD combined IFC groupActive comparatorThe patients were randomly assigned to the SIT group. The patients received combined therapy with shortwave diathermy (SWD) and interferential current (IFC) performed by the same physiotherapist at each treatment session.
Receives: Device: SWD combined IFC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from pre-enrollment in Visual analog scale (VAS) at 5th and 8th week after first intervention

    a scale from 0 through 100 (0 for no pain and 100 for the worst pain)

    Measured: pre-enrollment, 5th and 8th week after first intervention

Secondary outcomes (2)
  1. Change from pre-enrollment in The Oswestry disability index (ODI, in Chinese) at 5th and 8th week after first intervention

    There are six statements to be ranked on a scale of 0 to 5 in each of the 10 sections of the questionnaire. The contents relate to impairments such as pain intensity and abilities in personal care, lifting, walking, sitting, standing, sleeping, sex life, social life and traveling. The patients were asked to identify the corresponding level of disability in each section. The total score ranges from 0 to 50; 0 represents the highest level of function, and 50 indicates completely disabled.

    Measured: pre-enrollment, 5th and 8th week after first intervention

  2. Change from pre-enrollment in Self-reported satisfaction scales at 8th week after first intervention

    A 5-level scale was used for evaluation at the 8th week after treatment. The excellent and good scores were categorized into one group, and the acceptable and poor scores were categorized into another group for comparison.

    Measured: 8th week after first intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Dec 2014 (estimated)
  2. Study startNov 2012
  3. Primary completionNov 2013
  4. Study completionNov 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
42 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02313324
Sponsor's protocol ID
kmutth-101-023
Acronym
ESWT
Status last verified
Nov 2012
First submitted
3 Dec 2014
Last updated
10 Dec 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Lin SF, Chen YJ, Tu HP, Lee CL, Hsieh CL, Wu WL, Chen CH. The Effects of Extracorporeal Shock Wave Therapy in Patients with Coccydynia: A Randomized Controlled Trial. PLoS One. 2015 Nov 10;10(11):e0142475. doi: 10.1371/journal.pone.0142475. eCollection 2015.

    PubMed 26556601

Questions about this trial

What is this clinical trial studying?

A study testing Extracorporeal shock wave therapy (ESWT) and SWD combined IFC in people with Coccydynia, run by Kaohsiung Medical University Chung-Ho Memorial Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from pre-enrollment in Visual analog scale (VAS) at 5th and 8th week after first intervention (time frame: pre-enrollment, 5th and 8th week after first intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02313324, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in